

Sub B
55. The anticode oligomer of Claim 54, wherein said anticode oligomer is an antisense oligonucleotide complementary to a portion of the region of the splice acceptor site or splice donor site of the pre-mRNA encoding the bcl-2 gene.

Sub C cont'd
56. An anticode oligomer, wherein said anticode oligomer is an antisense oligonucleotide complementary to a portion of the 5' untranslated region of the bcl-2 mRNA.

D (cont'd)
57. The anticode oligomer of ~~Claim~~ 53, 54, 55 or 56; and a pharmaceutically acceptable carrier.

Sub E
58. The anticode oligomer of Claim 53, 54, 55 or 56, wherein said anticode oligomer contains at least one phosphorothioate-modified nucleotide and is complementary to a portion of the pre-mRNA or mRNA encoding the bcl-2 gene.

59. The anticode oligomer of Claim 58; and a pharmaceutically acceptable carrier.

60. The anticode oligomer of Claim 58, wherein said anticode oligomer is a phosphodiester/phosphorothioate chimera.

61. The anticode oligomer of Claim 60 wherein the oligonucleotide comprises at least 2 to 3 phosphorothioate linkages.

62. The anticode oligomer of Claim 60 or 61; and a pharmaceutically acceptable carrier.

Sub E
63. The anticode oligomer of Claim 53, 54, 55 or 56, wherein said anticode oligomer contains at least one phosphoramidate-modified nucleotide and is complementary to a portion of the pre-mRNA or mRNA encoding the bcl-2 gene.

REMARKS

Claims 32-52 were pending in this application. Claims 32-52 have been canceled without prejudice to Applicant's right to pursue the subject matter of the canceled claims in